The Australian Synchrotron is proud to be growing Australia’s capacity for innovative drug development, facilitating the advance of world-class disease and drug research through to local drug trials. Recent success in clinical trials of Venetoclax, the chronic lymphocytic leukaemia (CLL) drug developed by researchers from the Walter and Eliza Hall Institute and two international pharmaceutical companies is driving a major shift in the treatment of a range of blood cancers, according to a media information from the Peter MacCallum Cancer Centre. A clinical trial testing the drug for CLL is being undertaken at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.  The drug is also being tested for a type of lymphoma in the US. Micro-crystallography on the MX2 beamline was used for structural biology studies of the drug during development. Read more on Peter MacCallum Cancer Centre website report.  Read about how the Australian Synchrotron contributed to the research that led to the development of the drug in this report.